The Effectiveness of Curcumin, Resveratrol, and Silymarin on MASLD : A Systematic Review and Meta‐Analysis

作者：Qian Huang, Ziming An, Xin Xin, Xiaojun Gou, Xiaoting Tian, Yiyang Hu, Zubing Mei, Qin Feng · 发表于：Food Science & Nutrition · 年份：2024 · DOI：10.1002/fsn3.4595 · 被引用次数：22 · 研究领域：Liver Disease Diagnosis and Treatment、Diet, Metabolism, and Disease、Liver Disease and Transplantation

ABSTRACT Polyphenols, known for their potent antioxidant and anti‐inflammatory properties, have emerged as promising, natural, and safe complementary treatment options for metabolic‐associated steatotic liver disease (MASLD). Among these, curcumin, resveratrol, and silymarin are the most extensively studied; however, their differential effects on MASLD outcomes remain inconclusive. This systematic review and meta‐analysis of RCTs aimed to evaluate the efficacy of curcumin, resveratrol, and silymarin in patients with MASLD. A comprehensive search of seven databases was conducted up to September 2024. Odds ratios (OR), mean differences (MD), and standardized MD (SMD) with 95% confidence intervals (CI) were used to assess treatment effects. Primary outcomes included improvement in hepatic steatosis and ALT activity, while secondary outcomes included changes in AST activity, blood lipids, glucose, BMI, blood pressure, and TNF‐α. Twenty‐seven studies involving 1691 participants were included. Curcumin significantly improved hepatic steatosis compared to placebo (OR: 4.39, 95% CI: 1.45 to 13.27, p = 0.009), followed by resveratrol (OR: 3.18, 95% CI: 1.20 to 8.42, p = 0.02). Silymarin exhibited the strongest effect in reducing ALT levels (MD: −6.44 U/L, 95% CI: −10.03 to −2.85, p = 0.0004), with curcumin (MD: −5.88 U/L, 95% CI: −9.05 to −2.72, p = 0.0003) also showing significant reductions. A marked reduction in AST was observed with silymarin (MD: −6.99 U/L, 95% CI: −8.56 to −5.42...